Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 16/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.53 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | MARK3 | P27448 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28816290 | 0.85 | HTT (0.71) | HTT | |
| SCHEMBL29886352 | 0.85 | HTT (0.71) | HTT | |
| SCHEMBL3740650 | 0.84 | MAP4K4 (0.54) | HTTS1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL17055825 | 0.82 | HTT (0.62) | HTTS1PR1S1PR5 | |
| SCHEMBL1420226 | 0.80 | S1PR1 (0.69) | S1PR1S1PR3MAP4K4MINK1S1PR5 | |
| SCHEMBL3930124 | 0.80 | ACR (0.57) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3230760 | 0.79 | HTT (0.68) | HTT | |
| SCHEMBL3745599 | 0.78 | MAP4K4 (0.56) | S1PR1S1PR3MAP4K4MINK1S1PR5 | |
| SCHEMBL3741047 | 0.77 | S1PR1 (0.73) | S1PR1S1PR3MAP4K4MINK1S1PR5 | |
| SCHEMBL28816448 | 0.77 | HTT (0.66) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | HTT 4359/4885S1PR1 1120/4885S1PR3 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.